Drug Profile
AK 10
Alternative Names: AK10Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Aetas Pharma
- Class Heart failure therapies
- Mechanism of Action Troponin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute heart failure; Chronic heart failure
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Acute-heart-failure in Japan
- 28 Sep 2021 No recent reports of development identified for research development in Chronic-heart-failure in Japan
- 03 Aug 2017 Early research in Acute heart failure in Japan before August 2017 (Aetas Pharma pipeline, August 2017)